Cellular heterogeneity in vertical growth phase melanoma

Archives of Pathology and Laboratory Medicine

Volumn 134, Issue 12, 2010, Pages 1750-1757

  Laga, Alvaro C ^a   Murphy, George F ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INVASION; CANCER STEM CELL; CELL TRANSFORMATION; DISEASE COURSE; HUMAN; MELANOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SKIN TUMOR;

CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; MELANOMA; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; SKIN NEOPLASMS;

EID: 78650503726     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Clark WH Jr, Ten Heggeler B, Bretton R. Electron microscope observations of human cutaneous melanomas correlated with their biologic behavior. In: McCarthy WH, ed. Melanoma and Skin Cancer: Proceedings of the International Pigment Cell Conference. Sydney, Australia: VCN Blight; 1972:121-141.
2. Clark WH Jr, Ainsworth AM, Bernardino EA, Yang CH, Mihm CM Jr, Reed RJ. The developmental biology of primary human malignant melanoma. Semin Oncol. 1975;2(2):83-103.
3. Clark WH Jr, Elder DE, Van Horn M. The biologic forms of malignant melanoma. Hum Pathol. 1986;17(5):443-450.
4. Alonso SR, Ortiz P, Pollán M, et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarraybased study. Am J Pathol. 2004;164(1):193-203.
5. Baruthio F, Quadroni M, Rüegg C, Mariotti A. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. Proteomics. 2008;8(22):4733-4747.
6. Sousa JF, Espreafico EM. Suppression subtractive hybridization profiles of radial growth phase and metastatic melanoma cell lines reveal novel potential targets. BMC Cancer. 2008;8:19-37.
7. Elder DE, Guerry DIV, Epstein MN, et al. Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol. 1984;6:55-61.
8. Nyormoi O, Bar-Eli M. Transcriptional regulation of metastasis-related genes in human melanoma. Clin Exp Metastasis. 2003;20(3):251-263. (Pubitemid 36513229)
9. Magnoni C, Tenedini E, Ferrari F, et al. Transcriptional profiles in melanocytes from clinically unaffected skin distinguish the neoplastic growth pattern in patients with melanoma. Br J Dermatol. 2007;156(1):62-71.
10. Elder DE, Murphy GF. Malignant tumors (melanomas and related lesions). In: Elder DE, Murphy GF, eds. Melanocytic Tumors of the Skin, 4th ed. Washington, DC: Armed Forces Institute of Pathology; 2009. Atlas of Tumor Pathology, 3rd series, fascicle 2. In press.
11. Gimotty PA, Van Belle P, Elder DE, et al. Biologic and prognostic significance of dermal Ki67 expression, mitoses, and tumorigenicity in thin invasive cutaneous melanoma. J Clin Oncol. 2005;23(31):8048-8056.
12. Gimotty PA, Guerry D, Ming ME, et al. Thin primary cutaneous malignant melanoma: a prognostic tree for 10-year metastasis is more accurate than American Joint Committee on Cancer Staging. J Clin Oncol. 2004;22(18):3668-3676.
13. Clark WH Jr, Elder DE, Guerry DIV. Dysplastic nevi and malignant melanoma. In: Farmer ER, Hood AF, eds. Pathology of the Skin. Norwalk, Connecticut: Appleton & Lange; 1990:682-754.
14. Clark WH Jr, Elder DE, Guerry DIV, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893-1904.
15. Bastian BC, Le Boit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization. Cancer Res. 1998;58(10):2170-2175.
16. Bastian BC, Kashani-Sabet M, Hamm H, et al. Gene amplifications characterize acral melanoma and permit the detection of occult tumor cells in the surrounding skin. Cancer Res. 2000;60(7):1968-1973.
17. Demunter A, Stas M, Degreef H, De Wolf-Peeters C, van den Oord JJ. Analysis of N-and K-ras mutations in the distinctive tumor progression phases of melanomas. J Invest Dermatol. 2001;117(6):1483-1489.
18. Heenan PJ, Holman CD. Nodular malignant melanoma: a distinct entity or a common end stage? Am J Dermatopathol. 1982;4(5):477-478.
19. Mihm MC Jr, Clark WH Jr, From L. The clinical diagnosis, classification and histogenetic concepts of the early stages of cutaneous malignant melanomas. N Engl J Med. 1971;284(19):1078-1082.
20. Leong, SP. Paradigm of metastasis for malignant melanoma. In: Hearing VJ, Leong SPL, eds. From Melanocytes to Melanoma: The Progression to Malignancy. 1st ed. Totowa, NJ: Humana; 2006:429-440.
21. Futreal PA, Coin L, Marshall M, et al. A census of human cancer genes. Nat Rev Cancer. 2004;4(3):177-183.
22. Vogelstein B, Kinzler KW. Cancer genes and the pathways they control. Nat Med. 2004;10(8):189-199.
23. Bruce WR, Van der Gaag H. A quantitative assay for the number of murine lymphoma cells capable of proliferation in vivo. Nature. 1963;199:79-80.
24. Fidler IJ, Hart IR. Biological diversity in metastatic neoplasms: origins and implications. Science. 1982;217(4564):998-1003.
25. Hamburger AW, Salmon SE. Primary bioassay of human tumor stem cells. Science. 1977;197(4302):461-463.
26. Brunschwig A, Southam CM, Levin AG. Host resistance to cancer: clinical experiments by homotransplants, autotransplants and admixture of autologous leukocytes. Ann Surg. 1965;162(3):416-425.
27. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536-540.
28. Hendrix MJ, Seftor EA, Hess AR, Seftor RE. Molecular plasticity of human melanoma cells. Oncogene. 2003;22(20):3070-3075.
29. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005;5(8):615-625.
30. Velazquez EF, Jungbluth AA, Yancovitz M, et al. Expression of the cancer/testis antigen NY-ESO-1 in primary and metastatic malignant melanoma (MM) - correlation with prognostic factors. Cancer Immun. 2007;7:11-18.
31. Rothhammer T, Wild PJ, Meyer S, et al. Bone morphogenic protein 7 (BMP7) expression is a potential novel prognostic marker for recurrence in patients with primary melanoma. Cancer Biomark. 2007;3(2):111-117.
32. Hsu MY, Rovinsky SA, Lai CY, et al. Aggressive melanoma cells escape from BMP-7 mediated autocrine growth inhibition through coordinated Noggin upregulation. Lab Invest. 2008;88(8):842-855.
33. Balint K, Xiao M, Pinnix CC, et al. Activation of Notch1 signaling is required for β-catenin-mediated human primary melanoma progression. J Clin Invest. 2005;115(11):3166-3176.
34. Weeraratna AT, Jiang Y, Hostetter G, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1(3):279-288.
35. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65(10):4320-4333.
36. Klein WM, Wu BP, Zhao S, Wu H, Klein-Szanto AJ, Tahan SR. Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2007;20(1):102-107.
37. van Kempen LC, van den Oord JJ, van Muijen GN, et al. Activated leukocyte cell adhesion molecule/CD166, a marker of tumor progression in primary malignant melanoma of the skin. Am J Pathol. 2000;156(3):769-774.
38. Fang D, Nguyen TK, Leishear K, et al. A tumorigenic subpopulation with stem cell properties in melanomas. Cancer Res. 2005;65(20):9328-9337.
39. Monzani E, Facchetti F, Galmozzi E, et al. Melanoma contains CD133 and ABCG2 positive cells with enhanced tumorigenic potential. Eur J Cancer. 2007;43(5):935-946.
40. Topczewska JM, Postovit LM, Margaryan NV, et al. Embryonic and tumorigenic pathways converge via Nodal signaling: role in melanoma aggressiveness. Nat Med. 2006;12(8):925-932.
41. Schatton T, Murphy GF, Frank NY, et al. Identification of cells initiating human melanomas. Nature. 451(7176):345-349.
42. Elliott AM, Al-Hajj MA. ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009;7(1):79-87.
43. Suryo Rahmanto Y, Dunn LL, Richardson DR. The melanoma tumor antigen, melanotransferrin (p97): a 25 year hallmark-from iron metabolism to tumorigenesis. Oncogene. 2007;26(42):6113-6124.
44. Postovit LM, Margaryan NV, Seftor EA, Hendrix MJC. Role of nodal signaling and the microenvironment underlying melanoma plasticity. Pigment Cell Melanoma Res. 2008;21(3):348-357.
45. Hochedlinger K, Blelloch R, Brennan C, et al. Reprogramming of a melanoma genome by nuclear transplantation. Genes Dev. 2004;18(15):1875-1885.
46. Hsu MY, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic proteins in melanoma: angel or devil? Cancer Metastasis Rev. 2005;24(2):251-263.